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Regulating Medicines in a Globalized World With Increased
Recognition and Reliance Among Regulators
A National Academies Report
Research and development of pharmaceuticals are now
complex global endeavors, with drug companies oper-
ating worldwide using global supply chains.1 Pharma-
ceutical companies source their products from many
countries, conduct trials in multiple sites, and market es-
sential drugs and vaccines globally. Yet oversight of drug
safety and effectiveness is primarily the responsibility of
national regulators of variable capacities. National agen-
cies often undertake product reviews without recogniz-
ing that similar reviews are occurring elsewhere, some-
times simultaneously.2 The result is duplication and
redundancy, which benefits neither national nor global
public health. Supported by the US Food and Drug
Administration (FDA), the National Academies of
Sciences, Engineering, and Medicine convened an ex-
pert committee to explore the benefits of mutual rec-
ognition and other reliance activities among regulators.3
Even well-resourced regulators (for example, the
FDA, the European Medicines Agency, the Pharmaceu-
tical and Medical Devices Agency Japan, and Health
Canada) find it difficult to ensure the safety, efficacy,
and quality of medicines in a globalized world.1 Reg-
ulatory failures cause harm to the population and
undermine public trust in government. In 2008, follow-
ing discovery of contaminated heparin originating
from China, the Bush administration authorized the
FDA to coordinate certain product manufacturing
inspections with Australian and European regulators in
China and India—setting the stage for “third country”
inspections (ie, inspections conducted outside the
jurisdiction of either regulator).4 Yet concerns about
the quality of active pharmaceutical ingredients and
finished pharmaceutical products persist. For example,
in 2018, the FDA recalled generic medications used to
treat hypertension and cardiovascular disease because
of contamination.5
Reliance Strategies to Enhance Regulatory Oversight
No regulator, even if highly resourced, has the capacity
to fully protect the public’s health. Given finite human
and financial resources, the National Academies com-
mittee proposed recognition and reliance arrange-
ments to respond to the mounting complexity of regu-
latory oversight. Thus, agencies should increasingly rely
on and actively cooperate with other trusted regula-
tory authorities.
Recognition and reliance leverage the work and
work products (such as inspection or scientific assess-
ment reports) of trusted regulatory authorities. Recog-
nition and reliance can be informal (eg, scientific collabo-
ration) or formal depending on the extent to which
agencies are required by law to share information.
“Recognition” is a formal type of reliance, with mutual rec-
ognition agreements (MRAs) being the most stringent.
Countries negotiate MRAs typically as part of interna-
tional trade agreements. National sovereignty is main-
tained because each government ultimately controls its
own regulatory approvals based on its population’s needs
and legal traditions.
A country’s strategy for reliance often depends on
its capacities. Well-resourced and moderately well-
resourced regulatory authorities should increase trans-
parency and information sharing and ultimately share
tasks like inspections. Lower-resourced
regulatory authorities could consider
unilateral recognition with trusted au-
thorities. If the FDA or the European
Medicines Agency, for example, were
to approve a new product, a lower-
resourced country might rely on, or even
recognize, such approval. However,
such recognition needs to be for the iden-
tical preparation or product.
Beyond government policy, industry and patient/
consumer groups have major roles. Industry, for ex-
ample, could reduce redactions in its reporting require-
ments by waiving unnecessarily broad definitions
of trade secrets. Transparency would contribute to
more informed decision-making. Patient and consumer
groups should push for a public health framing of all
recognition and reliance arrangements to secure the
global public good of safe, effective medicines for all
populations throughout the world. The public should
have trust that pharmaceuticals everywhere are manu-
factured to the same high standards demanded by the
best-resourced regulators.
Building Better Reliance Arrangements
In an environment of limited human and financial
resources, unprecedented globalization, and societal
demands for faster drug approvals, medicines regula-
tors have sought to improve and expedite regulatory
oversight. The National Academies committee offered
the following recommendations to help regulatory
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pharmaceuticals everywhere are
manufactured to the same high
standards demanded by the
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authorities cope with the growing workload and complexity of
medicines regulation.
Improving Public Health Through Better-Designed MRAs
Mutual recognition agreements are legally binding agreements
allowing one regulatory authority to trust the work products of
another agency as equivalent to its own. Currently, 14 MRAs exist
between well-resourced or moderately well-resourced regulatory
authorities. The European Union has the most MRAs, including
with Australia, Canada, Japan, Singapore, and, as of July 2019, the
United States. Because MRAs are part of trade agreements, they
are primarily negotiated by trade representatives. Because MRAs
have strong public health implications, medicines regulators, rather
than trade representatives, are in the best position to design, nego-
tiate, and ultimately implement MRAs.
Responding to Evolving Science and Technology
Pharmaceuticals are rapidly evolving, presenting new challenges to
regulators. Yet because they are embedded within trade agree-
ments, MRAs cannot be easily adjusted. The committee therefore
recommended that governments give broad and flexible powers to
regulatory agencies to set up or amend MRAs and other reliance ar-
rangements. Flexibility and agility will enable agencies to respond
to the rapid pace of change in science and technology.
Better Utilization of the European Union–United States MRA
Mutual recognition agreements primarily focus on sharing inspec-
tion reports and certifications related to good manufacturing prac-
tices. The MRA between the European Union and the United
States includes a limited range of products, although it does have
provisions for expanding its product coverage and reliance mea-
sures, such as with third-country inspections. The committee
urged the European Union and the FDA to immediately implement
and expand oversight in countries with weaker regulatory systems
and large production and manufacturing sites, like China and India.
Because a growing share of new pharmaceuticals are sourced or
manufactured in these countries, enhanced and shared interna-
tional oversight is essential.
Information Sharing Among Medicines Regulators
Given large workloads and finite resources, it is important to
maximize a regulatory authority’s human and financial capital.
Making work products of regulators easily accessible (eg, through
limited redactions) to trusted authorities conserves scarce
resources by avoiding duplicative work performed by other
trusted agencies. The committee therefore recommended a sys-
tematic review of all agency policies and procedures to reduce the
burden of regulatory redundancy.
Evaluating Public Health Influence of MRAs
Mutual recognition agreements have been in existence for 2 de-
cades, yet there remains a dearth of quantitative data analyzing their
public health influence. Anecdotally, multiple stakeholders report
that MRAs are valuable tools for avoiding duplication of work. How-
ever, the committee recommends that regulatory authorities work
cooperatively to create a results framework for monitoring and mea-
suring outcomes and effects of recognition and reliance arrange-
ments. Evaluating performance and then acting on high-quality evi-
dence will ensure a stronger future for pharmaceutical regulation to
improve global public health.
The Future of Regulatory Oversight
The public relies on regulators to ensure the safety and efficacy of
essential vaccines and medicines. This core regulatory responsibil-
ity is placed at risk by the complex and rapidly evolving develop-
ment of modern pharmaceuticals. Medicines have developed from
simple molecules to highly complex elements requiring extensive
expertise. At the same time, supply chains have become global-
ized. Elements of a medicine may be manufactured in various coun-
tries and then incorporated into a finished product in yet another
country before being exported for sale. All of these advances re-
quire more efficient use of resources through recognition and reli-
ance. In today’s globalized world, regulatory authorities, regard-
less of resource level, cannot ensure rigorous public health oversight
of medicines across the life cycle. In the view of this expert commit-
tee, well-evaluated reliance arrangements must now be consid-
ered a 21st century best regulatory practice.
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